Suspension of trading

Venus Concept Inc.

VERO

US92332W3034

Advanced Medical Equipment & Technology

Market Closed - OTC Markets Other stock markets 12:44:37 2026-04-06 pm EDT			5-day change	1st Jan Change
0.3105 ^USD	+2.56%		-.--%	-79.02%

May. 13	Venus Concept Inc. Announces Senior Management Changes	CI
Apr. 08	Venus Concept Inc. announced that it has received $1.5 million in funding	CI

Venus Concept Inc. announced that it has received $1.5 million in funding

Published on 04/08/2026

S&P Capital IQ

VENUS CONCEPT INC.

+2.56%

On April 9, 2026, Venus Concept Inc. closed the transaction. The transaction included participation from two investors.

Latest news about Venus Concept Inc.

May. 13	Venus Concept Inc. Announces Senior Management Changes	CI
Apr. 08	Venus Concept Inc. announced that it has received $1.5 million in funding	CI
Mar. 25	Venus Concept Inc. announced that it expects to receive $1.5 million in funding	CI
Feb. 10	Venus Concept Inc.(NasdaqCM:VERO) dropped from S&P TMI Index	CI
Feb. 05	Venus Concept Inc.(OTCPK:VERO) dropped from NASDAQ Composite Index	CI
Jan. 21	Top Midday Decliners	MT
Jan. 21	Venus Concept announces intention to voluntary delist from Nasdaq and deregister with SEC	RE
Jan. 21	Top Premarket Gainers	MT
Jan. 21	Venus Concept Inc. Announces Voluntary Delisting from NASDAQ and Deregistration with SEC to Enhance Financial Efficiency	CI
Jan. 20	Top Premarket Decliners	MT
Jan. 16	Top Premarket Gainers	MT
Jan. 15	Madryn Asset Management Engages with Venus Concept Inc. on Cost Reduction and Strategic Initiatives Amid Debt Restructuring Efforts	CI
Jan. 07	Venus Concept Inc - On Dec 31, co & its unit enter consent agreement with Madryn Health Partners & others - SEC filing	RE
Nov. 13	Venus Concept Inc., Q3 2025 Earnings Call, Nov 13, 2025
Nov. 13	Venus Concept Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI

Venus Concept Inc. is a global medical technology company. The Company develops, commercializes and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies and related services and reaches over 60 countries and nine direct markets. The Companyâ€™s product portfolio consists of aesthetic device platforms, including Venus Versa, Venus Versa Pro, Venus Legacy, Venus Velocity, Venus Viva, Venus Glow, Venus Bliss, Venus Bliss MAX, Venus Epileve, Venus Viva MD and AI.ME. Its treatments for hair loss are divided into non-surgical options and surgical procedures. Its hair restoration systems include NeoGraft and the ARTAS iX Robotic Hair Restoration system. Its systems are designed on flexible platforms that enable it to expand beyond the aesthetic industryâ€™s traditional markets of dermatology and plastic surgery, and into non-traditional markets, including family medicine and general practitioners and aesthetic medical spas.

Employees

292

Sector

Advanced Medical Equipment & Technology

More about the company